GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharma Mar SA (WBO:PHM) » Definitions » Capex-to-Operating-Income

Pharma Mar (WBO:PHM) Capex-to-Operating-Income : 0.68 (As of Sep. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Pharma Mar Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Pharma Mar's Capital Expenditure for the three months ended in Sep. 2024 was €-3.70 Mil. Its Operating Income for the three months ended in Sep. 2024 was €5.46 Mil.

Hence, Pharma Mar's Capex-to-Operating-Income for the three months ended in Sep. 2024 was 0.68.


Pharma Mar Capex-to-Operating-Income Historical Data

The historical data trend for Pharma Mar's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharma Mar Capex-to-Operating-Income Chart

Pharma Mar Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.02 0.08 0.20 -

Pharma Mar Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 10.43 0.68

Competitive Comparison of Pharma Mar's Capex-to-Operating-Income

For the Biotechnology subindustry, Pharma Mar's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharma Mar's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharma Mar's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Pharma Mar's Capex-to-Operating-Income falls into.



Pharma Mar Capex-to-Operating-Income Calculation

Pharma Mar's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-15.956) / -4.098
=N/A

Pharma Mar's Capex-to-Operating-Income for the quarter that ended in Sep. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-3.697) / 5.458
=0.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharma Mar  (WBO:PHM) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Pharma Mar Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Pharma Mar's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharma Mar Business Description

Industry
Traded in Other Exchanges
Address
Avenida de los Reyes, 1, Poligono Industrial La Mina-norte, Colmenar Viejo, Madrid, ESP, 28770
Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and market insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology, Diagnostics, Consumer chemicals, and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.